Last reviewed · How we verify
NCT02635841
Compassionate Use of Deferiprone in Patients With PKAN
trial testing Deferiprone in Pantothenate Kinase-Associated Neurodegeneration. No longer available.
Quick facts
| Lead sponsor | Chiesi Canada Corp |
|---|---|
| Status | NO LONGER AVAILABLE |
| Study type | EXPANDED_ACCESS |
Drugs / interventions tested
- Deferiprone (DEFERIPRONE) — full drug profile →
Conditions studied
- Pantothenate Kinase-Associated Neurodegeneration — all drugs for Pantothenate Kinase-Associated Neurodegeneration →
Sponsor
Chiesi Canada Corp
Who can join
7 and older, any sex, with Pantothenate Kinase-Associated Neurodegeneration. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patients with pantothenate kinase-associated neurodegeneration (PKAN) who have completed the ApoPharma-sponsored study TIRCON2012V1-EXT and who wish to continue to take deferiprone will be offered the opportunity to receive it on a compassionate basis. Patients will be followed locally by their own neurologist or other appropriate specialist.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Towards Precision Therapies for Inherited Disorders of Neurodegeneration with Brain Iron Accumulation.
Spaull RVV, Soo AKS, Hogarth P, Hayflick SJ, et al · · 2021 · cited 14× · PMID 34909266 · DOI 10.5334/tohm.661 -
When Pathways Converge: Iron, Lipid Peroxidation, and α-Synuclein in Ferroptosis-Driven Dopaminergic Neurodegeneration.
Sperlich CL, Stockwell BR, Farina M. · · 2026 · PMID 41968973 · DOI 10.1111/jnc.70438
Verify or expand the search:
- PubMed search for NCT02635841
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Deferiprone
Trials testing the same drug.
- NCT07023666 — Early Screening and Treatment of Heart Complication in Sickle Cell Disease · Phase 2 · recruiting
- NCT03293069 — Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis · Phase 2, PHASE3 · completed
- NCT02728843 — Study of Parkinson's Early Stage With Deferiprone · Phase 2 · completed
- NCT02655315 — Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease · Phase 2 · completed
- NCT02443545 — Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other Anemias · Phase 4 · terminated
Other Chiesi Canada Corp trials
Trials by the same sponsor.
- NCT03591575 — Safety and Efficacy of Early Treatment With Deferiprone in Infants and Young Children · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02635841 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chiesi Canada Corp
- Last refreshed: 14 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02635841.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing